Please login to the form below
Ovarian canncer
This page shows the latest Ovarian canncer news and features for those working in and with pharma, biotech and healthcare.
Another NICE no for AZ’s new ovarian cancer drug
Cost watchdog wants more information for Lynparza. . NICE is once again saying no to AstraZeneca's new ovarian cancer drug - but is opening up a second consultation on its decision. ... The Institute is minded, in preliminary draft guidance, to reject
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Featured jobs
- Account Director – London based Medical Communications Agency
-
Excellent Remuneration Package
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
- FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...
-
Excellent Daily Rate
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
-
Account Director – UK Office
-
Excellent salary and benefits
- Account Director - Medical Communications - London / South East
-
Excellent Salary and Benefits on offer
- Account Director, Healthcare Communications
-
Salary TBC
Subscribe to our email news alerts
- GSK hires Merck KGaA exec to lead US pharma business
- Novartis chooses internal replacement for US pharma president role
- Moving annual total (MAT)
- Roche undercuts price of Bayer cancer drug after winning FDA approval
- Novartis chooses internal replacement for US pharma president role
- Lilly psoriasis drug beats J&J's Tremfya in head-to-head trial
- FDA rejects Sarepta’s new Duchenne drug over safety fears
- AZ claims first-in-class win for Farxiga in heart failure
- UK no longer measles-free as vaccination rates fall dramatically
- Lilly’s Levi Garraway will replace Sandra Horning as Roche CMO
- Blended Intelligence
- Planning a pharma exhibition stand? You must read this!
PMHub
SEVEN STONES
Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....
Latest intelligence
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
- The relevance of patient perspectives to value
- Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
- How is the NHS Long-term Plan being put into action?
- Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
Quick links
Infographics
